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Patients with a strong family history of breast cancer are often counseled to receive genetic screening for BRCA1
and BRCA2 mutations, the strongest known predictors of breast cancer. A major limitation of genetic testing is
the number of inconclusive results due to unclassified BRCA1 and BRCA2 sequence variants. Many known dele-
terious BRCA1 and BRCA2 mutations affect splicing, and these typically lie near intron/exon boundaries. However,
there are also potential internal exonic mutations that disrupt functional exonic splicing enhancer (ESE) sequences,
resulting in exon skipping. Using previously established sequence matrices for the scoring of putative ESE motifs,
we have systematically examined several BRCA2 mutations for potential ESE disruption mutations. These predic-
tions revealed that BRCA2 T2722R (8393CrG), which segregates with affected individuals in a family with breast
cancer, disrupts three potential ESE sites. Reverse-transcriptase polymerase chain reaction analysis confirms that
this mutation causes exon skipping, leading to an out-of-frame fusion of BRCA2 exons 17 and 19. This represents
the first BRCA2 missense mutation shown to be a predicted deleterious protein-truncating mutation and suggests
a potentially useful method for determining the clinical significance of a subset of the many unclassified variants
in BRCA1 and BRCA2.
Breast cancer is a leading cause of cancer deaths among
women and is expected to claim the lives of 140,000
individuals in the United States in 2002 (see “Breast Can-
cer Facts and Figures 2001–2002” at the American Can-
cer Society Web site). The majority of breast cancer cases
occur sporadically, but 5%–10% of cases are caused
by inherited mutations in the breast cancer–susceptibil-
ity genes BRCA1 (MIM 113705) and BRCA2 (MIM
600185). Mutations inBRCA1 andBRCA2 predict prob-
abilities of breast cancer by age 70 years of 45%–87%
and 26%–84%, respectively, making these the strongest
predictors of breast cancer known (Ford et al. 1994, 1998;
Struewing et al. 1997; Thorlacius et al. 1998; Antoniou
2000; Satagopan 2001). Thus, patients with a strong fam-
ily history of breast and ovarian cancer are counseled
to receive genetic testing for mutations in BRCA1 and
BRCA2.
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In the Breast Cancer Linkage Consortium data set
(Ford et al. 1998), linkage toBRCA1 orBRCA2 is found
in as many as 84% of patients with breast cancer in
families with strong family history. However, in other
data sets, the rates of deleterious mutations in BRCA1
or BRCA2 are lower, ranging from 16% to 26% for
BRCA1 (Couch et al. 1997; Ganguly et al. 1997; Frank
et al. 1998) and from 7% to 13% for BRCA2 (Ganguly
et al. 1997; Frank et al. 1998). Mutation rates are even
lower when family history is not used in data set–selec-
tion criteria (Krainer et al. 1997; Southey and Hopper
1999; Shih et al. 2002). Most reported disease-associ-
ated alleles of BRCA1 and BRCA2 are small insertions,
deletions, or splice-site mutations that result in protein
truncation. Only a small number of amino acid substi-
tutions in either gene have been described as deleterious
missense mutations, yet a very large number of different
unclassified variant alleles are routinely encountered in
clinical and research laboratories. In our recent study (J.
D. Fackenthal, L. Sveen, Q. Gao, E. K. Kohlmeir, J.
Jensen, C. Adebamowo, T. O. Ogundiran, A. A. Adeni-
pekun, R. Oyesegun, O. Campbell, E. E. U. Akang, S.
Das, and O. I. Olopade, unpublished data), 68% of
BRCA2 sequences from a hospital-based cohort of Ni-
gerian patients with breast cancer who were age 40 years
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Figure 1 The sequence surrounding the CrG transversion at
BRCA2 base 8393 (gray square) in humans, and the homologous
regions in mouse, rat, and chicken. BRCA2 T2722R results from a
CrG transversion at this base. The top line (italics) in each panel
represents the amino acid sequence, and the second line represents the
base sequence. The brackets show high-scoring protein-binding motifs
for the SR proteins listed on the left. Values in parentheses are the
actual scores for the wild-type (left) and mutant (right) sequences for
each motif. Note that there are three overlapping high-scoring SF2/
ASF motifs for the mouse/rat sequence. The CrG transversion has
been detected only in the present study.
or younger had variations of some kind, but only 14%
could be classified as deleterious alleles or polymor-
phisms. Likewise, in our clinic-based cohort at the Uni-
versity of Chicago Cancer Risk Clinic, 30/89 (34%) pa-
tients tested had BRCA2 alterations of some kind, and
64% of these (16/25 different alleles) were either novel
alleles or described as “unclassified” variants in the
Breast Cancer Information Core (BIC) Web site (J. D.
Fackenthal, L. Sveen, Q. Gao, E. K. Kohlmeir, J. Jensen,
C. Adebamowo, T. O. Ogundiran, A. A. Adenipekun,
R. Oyesegun, O. Campbell, E. E. U. Akang, S. Das, and
O. I. Olopade, unpublished data). These findings are
consistent with other reports that show high frequencies
of BRCA2 variations but low frequencies of predicted
deleterious protein-truncating BRCA2 mutations in pa-
tients with breast cancer, especially those of African an-
cestry (Wagner et al. 1999).
It is therefore necessary to define these unclassified var-
iants functionally as deleterious missense alleles, low-pen-
etrance alleles, or benign polymorphisms. Unfortunately,
no generally accepted functional test for either BRCA1
or BRCA2 exists. To address the clinical relevance of a
subset of these alleles, we are examining those base sub-
stitutions that might lead to splicing errors resulting in
protein truncation. Most BRCA1 and BRCA2 mutations
known to affect splicing lie at intron/exon boundaries.
However, the Glu1694Ter allele of BRCA1, which carries
a GrT transversion within exon 18, causes exon skipping
that results in an in-frame splice between exons 17 and
19 (Mazoyer et al. 1998; Liu et al. 2001). This GrT base
substitution disrupts a consensus exonic splicing enhancer
(ESE) motif that is likely bound by the SF2/ASF serine/
arginine-rich (SR) protein, one of several related proteins
that bind ESEs to identify exonic sequences during pre-
mRNA splicing. In addition, mutations that cause exon
skipping without disrupting consensus splice-site se-
quences have been found in several disease-related genes,
including CFTR, FACVIII, FANCC, FBN1, HPRT1,
ATP7A, NF1, OAT, WASP, and HEXB, reviewed by Val-
entine (1998) and Cartegni et al. (2002). In each of these
genes, one or more mutations associated with exon skip-
ping disrupts a putative ESE motif, indicating that this
may be a prevalent phenomenon in disease-related genes
(Liu et al. 2001).
To determine whether other mutations associated with
putative ESE motifs in BRCA1 or BRCA2 may be pre-
dicted from sequence analysis, we used previously es-
tablished sequence matrices for scoring likely ESE motifs
(Liu et al. 1998, 2000; Cartegni and Krainer 2002; Car-
tegni et al. 2002). In these studies, sequences with in
vitro ESE activity were identified for several SR proteins,
and consensus motifs were derived from these sequences.
Matrices were then derived that assigned a score for each
base in each position of the SR protein-binding site, as
shown by Cartegni et al. (2002).
To identify candidates for ESE-disruption alleles, we
examined 23 different exonic single-base BRCA2 sub-
stitutions identified in the University of Chicago Cancer
Risk Clinic, where genetic testing is performed according
to institutional-review-board–approved protocols after
informed consent is obtained. These alleles were found
in 41 individuals in 22 different families. Five of these
alleles fell within predicted ESE sequences, and four of
these base substitutions were predicted to disrupt ESE
function. Of these, only one allele, BRCA2 T2722R,
segregated with affected members of a family with breast
cancer (family number 98-11). The other alleles occurred
in families for which insufficient data were available to
ascertain cosegregation or occurred in conjunction with
known deleterious mutations that would mask the po-
tential effects of deleterious ESE mutations.
BRCA2 T2722R results from a CrG transition at base
8393 in BRCA2 exon 18. We determined that BRCA2
8393CrG lies within overlapping high-score motifs for
three SR proteins: SF2/ASF, SRp40, and SRp55 (fig. 1).
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Table 1
BRCA2 8393CrG Disruption of Three
High-Score ESE Motifs
SR Protein
Motif
Threshold
Wild-Type
Score
CrG
Score
SF2/ASF 1.956 3.09 1.51
SRp40 2.670 3.63 1.91
SRp55 2.676 3.74 .68
Figure 2 Family 98-11. Circles denote female individuals,
squares denote male individuals, and diamonds denote individuals for
whom sex was not reported. Slash marks indicate individuals who
have died. The arrow indicates the proband. Blackened shapes denote
affected individuals, unblackened shapes denote unaffected individu-
als, and half-blackened shapes denote individuals in whom the disease
was reported but not confirmed. Causes of death are as follows: in-
dividual II-1, stage 4 non–small cell lung cancer; individual II-3, liver
cancer; individual I-1, acute myocardial infarction; individual I-2,
ovarian cancer; and individual I-7, unknown.
In all three cases, the CrG transversion decreases the
motif score to a value well below the respective threshold
(table 1). If any one of these potential SR protein motifs
is a functional ESE, we predict that its disruption would
cause an exon-skipping pre-mRNA splicing defect, re-
sulting in an out-of-frame fusion between exons 17 and
19.
To test directly whether the 8393CrG transversion
disrupts functional ESE activity, we performed an RT-
PCR assay using blood cell mRNA from patient III-2
(fig. 2). Ten milliliters of patient blood was diluted with
6 ml of PBS, was added to 3 ml of Ficoll (Amersham/
Pharmacia Biotechnology), and was then spun for 15
min at 2,800 rpm at 18C. B-lymphocytes were collected
from the interface, counted, and checked for viability.
The cells were washed with PBS several times, were re-
suspended in FBS (BioWhittaker), were added to a glyc-
erol/Roswell Park Memorial Institute (RPMI; Invitro-
gen) buffer, and were frozen in liquid nitrogen. Thawed
cells were processed using the Absolutely RNA RT-PCR
Miniprep Kit, according to instructions provided by
Stratagene. The RT-PCR was performed using the Super-
Script One-Step RT-PCR with Platinum Taq, according
to instructions provided by Life Technologies. Primers
to exons flanking exon 18 were used: forward, TGGAA-
ACTGGCAGCTATGG; and reverse, CCTCCTGAAT-
TTTAGTGAATAAGGCTTCTAGTCTC. The thermo-
cycling profile was as follows: RT reaction (50C for 30
min, 94C for 2 min), followed by a touchdown three-
step PCR (95C for 30 s; 57C for 30 s, drop 0.5C per
cycle; 72C for 45 s) for 14 cycles, followed by a three-
step PCR (95C for 30 s, 50C for 30 s, 72C for 45 s)
for 35 cycles.
The expected full-length RT-PCR product is 730 bp,
whereas the predicted product from mRNA that ex-
cludes exon 18 is 375 bp. Figure 3 shows the results of
an RT-PCR using wild-type BRCA2 mRNA, which pro-
duces only a 730-bp fragment, whereas the same reac-
tion using mRNA from the heterozygous patient III-2
yields both the full-length and the predicted truncated
fragment. To show that this fragment represents an exon
18–skipping event, we cloned the PCR fragment and
sequenced three independent isolates in both orienta-
tions. All three contained the predicted splice junction
between BRCA2 exons 17 and 19 (fig. 4). The 3′ end
of exon 17 falls between the second and third positions
of codon 2659, and the 5′ end of exon 19 begins with
the first base in codon 2778. The out-of-frame splice
junction between exons 17 and 19 is predicted to add
42 novel codons to the 3′ end of codon 2659, followed
by a stop codon. The predicted truncation removes 927
wild-type amino acids from the carboxy terminus of the
BRCA2 protein and lies well upstream of other trun-
cating mutations known to be functionally null (Tavti-
gian et al. 1996; Peto et al. 1999). Unfortunately, there
was insufficient patient material available to demon-
strate the truncated protein with western analysis.
BRCA2 exon 18 is 355 bp long, and position 8393 lies
in the middle of this sequence (base 189). The 8393CrG
transversion therefore does not directly disrupt an intron/
exon splice site (Padgett et al. 1986; Shapiro and Sena-
pathy 1987), and no other base substitutions were de-
tected in BRCA2 in this family. Premature stop codons
often trigger nonsense-mediated mRNA decay (NMD)
(Maquat 1995; Zhang and Maquat 1997; Zhang et al.
1998; Sun et al. 2001). If NMD did affect the truncated
BRCA2 T2722R mRNA, it did not reduce message abun-
dance below the level of detection.
Since the RT-PCR amplification reaction shown in fig-
ure 3 likely reached saturation kinetics, we are unable to
determine the relative abundance of wild-type and trun-
cated mRNA species. We propose that the BRCA2
8393CrG transversion disrupts a functional ESE, creat-
628 Am. J. Hum. Genet. 71:625–631, 2002
Figure 3 RT-PCR products from patient mRNA with wild-type
BRCA2 (lane 2) or heterozygous for BRCA2 T2722R (lane 3).
Figure 4 Sequence of the exon 17/exon 18 junction in wild-type
BRCA2 (top) and of the exon17/exon 19 junction from the cloned
375-bp RT-PCR product from the BRCA2 T2722R heterozygote
(bottom).
ing a misspliced message predicted to encode a truncated,
nonfunctional protein. However, these data do not allow
us to determine which of the three SR protein motifs is
the functionally relevant sequence. Indeed, although it is
unlikely that each motif can be recognized simultaneously,
because of the overlap between them, it is possible that
each motif is important in a different cell type, depending
on the relative expression levels of SF2/ASF, SRp40, and
SRp55 (Zahler et al. 1993; Hanamura et al. 1998). It is
worth noting that putative SF2/ASF, SRp40, and SRp55
binding sites occur in BRCA2 homologs from mouse
(GenBank accession number XM_124706) and rat
(GenBank accession number NM_031542) at the position
homologous to human BRCA2 8393 (fig. 1). Indeed, the
mouse/rat sequence at this position carries three overlap-
ping sites for SF2/ASF, one of which is not reduced below
the threshold value by a hypothetical CrG transversion
similar to the human BRCA2 T2722R allele. In the ho-
mologous BRCA2 sequence in chicken (GenBank acces-
sion number AY083934), putative binding sites for SF2/
ASF and SRp40 are detected, but no SRp55 binding site
is detected using motif scores derived in human systems.
Although we cannot predict the SR protein-binding re-
quirements for each tissue in each species, we suggest that
the conservation of the SF2/ASF and SRp40 high-scoring
motifs may reflect a conserved role in BRCA2 splicing
regulation.
To determine whether the exon-skipping phenotype
associated with BRCA2 T2722R segregates with cancer,
we examined the occurrence of this allele in members
of family 98-11 (fig. 2). The proband (III-1) was diag-
nosed at age 38 years with an intraductal and invasive
left breast cancer. Histopathological analysis revealed a
poorly differentiated ductal carcinoma of intermediate
grade that was estrogen-receptor positive, progesterone-
receptor negative, and had a DNA index of 1.77 and
an S-phase fraction of 10.9%. In 1998, prior to definitive
surgery, the patient underwent genetic testing consisting
of complete sequencing of BRCA1 and BRCA2 at Myr-
iad Genetics Laboratory. BRCA2 T2722R was report-
ed and submitted to the BIC. At the time of analysis,
this finding was inconclusive. Nevertheless, the patient
elected to undergo a bilateral mastectomy, a total ab-
dominal hysterectomy, and bilateral salpingo-oophorec-
tomy, because of her extensive family history of breast/
ovarian cancer. The proband’s sister (III-2) received di-
agnoses of breast cancer at age 36 years and of ovarian
cancer at age 39 years. Their mother (II-2) received a
diagnosis of breast cancer at age 53 years, and her
mother (I-2) was found to have ovarian cancer at age
53 years. This family had other members with breast
cancer (I-7 and not shown), as well as lung cancer (II-
1 and not shown), liver cancer (II-3 and not shown),
colon cancer (I-1), stomach cancer (not shown), and
brain tumors (not shown). The presence of early-onset
breast cancer, multiple breast cancers among first-degree
relatives, and ovarian cancers, all in the same family, is
a strong indicator of a hereditary breast cancer syndrome
(Frank et al. 1998; Malone et al. 1998) and are consis-
tent with a deleterious mutation in either BRCA1 or
BRCA2. BRCA2 T2722R segregated with affected fam-
ily members II-2, III-1, and III-2, consistent with the
hypothesis that BRCA2 T2722R is a deleterious allele.
Unfortunately, the deleterious nature of this allele cannot
be demonstrated more rigorously by loss-of-heterozy-
gosity analysis of breast tumors from affected individ-
uals, because no tumors are available from this family.
Since this allele has never been detected previously and
is likely to be very rare, it would not be practical to
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attempt to determine its relative frequency in a large
cohort of affected and unaffected populations.
To our knowledge, these results provide the first ev-
idence for a BRCA2 missense mutation whose delete-
rious effect could be due to disruption of a functional
ESE. Unlike the previously described BRCA1 E1694X
ESE-disrupting mutation (Mazoyer et al. 1998), BRCA2
T2722R was initially thought to be an amino acid sub-
stitution variant, not a suspected truncating allele.
Deleterious mutations in BRCA1 and BRCA2 are
found in 27%–47% of patients with breast cancer who
have strong family histories of the disease, depending
on the selection criteria (Ganguly et al. 1997; Frank et
al. 1998; Lancaster et al. 1998). The remaining familial
breast cancers may be associated with mutations in an
as-yet-undiscovered BRCA3 gene or may arise from
complex genetic interactions between susceptibility
genes with limited penetrance and genetic modifiers.
However, it remains possible that a number of the cases
reported as unclassified variants for BRCA1 or BRCA2
actually represent deleterious mutations. Indeed, one
study showed that only 63% of the families with breast
cancer that show linkage to BRCA1 were associated
with definite deleterious mutations in BRCA1 (Ford et
al. 1998). One possible reason for this discrepancy may
be that inherited genomic rearrangements involving the
BRCA1 gene cannot be detected by direct sequencing.
Indeed, several studies have reported BRCA1 deletions
and frameshift-generating duplications that cannot be
detected by conventional PCR-based assays (Petrij-Bosch
et al. 1997; Puget et al. 1997, 1999; Swensen et al. 1997;
Montagna et al. 1999; Unger et al. 2000). Nonetheless,
we propose that another potential reason for the un-
derreporting of deleterious BRCA1/2 mutations may be
the presence of unrecognized ESE-disrupting mutations
among unclassified BRCA1/2 variants. We anticipate
that the use of predictive models for splicing mutations,
coupled with RT-PCR and/or protein analysis (when
available), will allow proper characterization of the bi-
ological relevance of some of these alleles. This ap-
proach, which does not require a functional assay for
the altered protein, may also allow reclassification of
some “unclassified variants” when additional family
members are not available for testing.
Predicted changes in protein primary structure often
help elucidate protein functional defects, especially when
genetic changes result in protein truncation or amino
acid substitutions in well-characterized functional do-
mains. The work presented here suggests that one should
consider the possibility of splicing defects and codon
changes when predicting the effects of base substitutions.
Because ESE sequences participate in exon definition
during splicing, a predicted silent base change could in
fact be a truncating mutation. Likewise, a predicted non-
sense or frameshifting mutation could result in an in-
frame junction between flanking exons, generating a
nonnull allele.
Previous studies have shown that mutated ESEs in
other genes cause a limited amount of exon skipping
(Shiga 1997; Stickeler 2001; Moseley 2002). This sug-
gests that ESE mutations that result in significant protein
truncations or deletions may not always be functionally
null but may represent alleles with limited penetrance.
As discussed above, we cannot preclude the possibility
that exon 18 from BRCA2 T2722R pre-mRNAs are
occasionally spliced correctly and are included in mature
mRNAs. If, as we suspect, BRCA2 T2722R has a del-
eterious effect, this could therefore result partly from a
loss of full-length BRCA2 mRNA and partly from a
protein-disrupting effect of the threonine-to-arginine
amino acid substitution. Indeed, as shown in figure 1,
both the putative ESE sequences and the amino acids
that they encode are conserved between human, mouse,
rat, and chicken. We cannot determine, from available
data, whether the selective pressure to retain these se-
quences acts at the level of splicing regulation, amino
acid identity, or both.
Several putative ESE sequences have been found in
exons where they have been sought systematically, rais-
ing the possibility of functional redundancy. This may
diminish the potential exon-skipping effect of a mutation
in any one ESE. However, in cases where 3–10 putative
ESE sequences occur within a single exon, a single ESE-
disrupting base substitution can lead to efficient exon
skipping (Liu et al. 2001; Cartegni and Krainer 2002).
This suggests that, at least in come cases, individual ESEs
may be critical for splicing even when other ESEs are
present in the same exon. Although it is difficult to pre-
dict the prevalence of ESE-disrupting mutations among
known BRCA1 or BRCA2 sequence variants, our recent
study of a Nigerian cohort with breast cancer suggests
that it might be highly prevalent (J. D. Fackenthal, L.
Sveen, Q. Gao, E. K. Kohlmeir, J. Jensen, C. Adeba-
mowo, T. O. Ogundiran, A. A. Adenipekun, R. Oye-
segun, O. Campbell, E. E. U. Akang, S. Das, and O. I.
Olopade, unpublished data). In that study, 5 of 20 (25%)
BRCA2 exonic base substitutions identified in a cohort
from Nigeria with early-onset breast cancer represented
potential ESE disruptions (no RNA samples are available
from these patients for RT-PCR analysis). Future work
will determine whether ESE-disrupting mutations in
BRCA1 and BRCA2 explain genetic susceptibility to
breast cancer in additional families with variants of un-
certain significance.
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